Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen Inc is poised for a positive financial outlook due to consistent revenue growth, achieving a compound annual growth rate (CAGR) of 13.6% over the past five fiscal years, demonstrating a strong market demand for its peripheral nerve repair technologies. The company has seen significant increases in reimbursement rates for allograft procedures, with ambulatory surgery center reimbursements rising 138% since 2019, which enhances the viability of its products in the healthcare market. Additionally, the rise in active breast resensation programs and increased productivity in high-potential accounts indicate robust surgical adoption and market penetration, suggesting a pathway towards sustainable profitability beginning in 2026.

Bears say

Axogen Inc faces significant risks that contribute to a negative outlook on its stock, including projected lower sales growth influenced by competitive pressures, regulatory issues, and the potential for technological obsolescence. The company has experienced historical net losses and relies heavily on product acceptance within the medical community, as well as key management, further complicating its path to sustainable profitability. Additionally, challenges related to operational scalability, regulatory approvals for the Avance biologic, and the implications of potential litigation over intellectual property rights could materially hinder Axogen's revenue growth and market share expansion.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.